Publication | Closed Access

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

ThrombosisHypertensionPulmonary Arterial HypertensionCardiovascular DiseaseAntihypertensive TherapyPlacebo-controlled StudyPharmacotherapyPhase 2Public HealthMedicinePulmonary Vascular DiseaseAnesthesiology